Kathan Mehta1, Annie Im2, Farah Rahman3, Hong Wang4, Peter Veldkamp5. 1. Division of Hematology-Oncology, University of Pittsburgh Medical Center Shadyside Hospital, Pennsylvania. 2. Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pennsylvania. 3. Department of Medicine, University of Pittsburgh, Pennsylvania. 4. Graduate School of Public Health, University of Pittsburgh, Pennsylvania. 5. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania.
Abstract
Background: Prior studies have shown that outcomes of hematopoietic stem cell transplantation (HSCT) in human immunodeficiency virus (HIV)-positive patients have been similar to outcomes in HIV-negative patients since effective implementation of highly active antiretroviral therapy by 1998, but they are limited by small sample size or noninclusion of recent data. Methods: We queried National Inpatient Sample, a large inpatient data set in the United States, from 1998 to 2012 for HSCT, using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 41.0. HIV-positive patients were identified by the presence of ICD-9-CM diagnostic codes 042, 043, 044, V08, and 079.53. The primary outcome was in-hospital mortality rate, and the secondary outcome the in-hospital complication rate of HSCT. Outcomes were assessed by means of univariate, multivariate regression and matched-pair analysis. Results: A total of 39517 patients who underwent HSCT were identified. Among these, 108 patients had HIV infection. There were no differences in in-hospital mortality rates or rates of intubation, sepsis, bacteremia, or graft-vs-host disease between HIV-positive and HIV-negative patients after allogeneic or autologous HSCT. In allogeneic HSCT, HIV-positive patients had a significantly higher incidence of nontuberculous mycobacterial and cytomegalovirus infection than HIV-negative patients. Conclusion: Although HIV-positive patients may have a higher risk of certain opportunistic infections, they are not at higher risk of serious in-hospital complications of HSCT. Allogeneic and autologous HSCT can be safely performed in HIV-positive patients.
Background: Prior studies have shown that outcomes of hematopoietic stem cell transplantation (HSCT) in human immunodeficiency virus (HIV)-positivepatients have been similar to outcomes in HIV-negative patients since effective implementation of highly active antiretroviral therapy by 1998, but they are limited by small sample size or noninclusion of recent data. Methods: We queried National Inpatient Sample, a large inpatient data set in the United States, from 1998 to 2012 for HSCT, using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 41.0. HIV-positive patients were identified by the presence of ICD-9-CM diagnostic codes 042, 043, 044, V08, and 079.53. The primary outcome was in-hospital mortality rate, and the secondary outcome the in-hospital complication rate of HSCT. Outcomes were assessed by means of univariate, multivariate regression and matched-pair analysis. Results: A total of 39517 patients who underwent HSCT were identified. Among these, 108 patients had HIV infection. There were no differences in in-hospital mortality rates or rates of intubation, sepsis, bacteremia, or graft-vs-host disease between HIV-positive and HIV-negative patients after allogeneic or autologous HSCT. In allogeneic HSCT, HIV-positive patients had a significantly higher incidence of nontuberculous mycobacterial and cytomegalovirus infection than HIV-negative patients. Conclusion: Although HIV-positive patients may have a higher risk of certain opportunistic infections, they are not at higher risk of serious in-hospital complications of HSCT. Allogeneic and autologous HSCT can be safely performed in HIV-positive patients.
Authors: Daniel D Murray; John Zaunders; Samuel T Milliken; C Mee Ling Munier; Carole Ford; C Orla Morrissey; Malini Visweswaran; Sharon Avery; Joseph Sasadeusz; John Kwan; Shrinivas Desai; Matthew Law; Kersten K Koelsch; Sharon R Lewin; John Moore; Anthony D Kelleher; Mark N Polizzotto Journal: Clin Infect Dis Date: 2021-04-08 Impact factor: 9.079
Authors: Richard F Ambinder; Juan Wu; Brent Logan; Christine M Durand; Ryan Shields; Uday R Popat; Richard F Little; Deborah K McMahon; Joshua Cyktor; John W Mellors; Ernesto Ayala; Lawrence D Kaplan; Ariela Noy; Richard J Jones; Alan Howard; Stephen J Forman; David Porter; Carlos Arce-Lara; Paul Shaughnessy; Lisa Sproat; Shahrukh K Hashmi; Adam M Mendizabal; Mary M Horowitz; Willis H Navarro; Joseph C Alvarnas Journal: Biol Blood Marrow Transplant Date: 2019-07-04 Impact factor: 5.742
Authors: Thomas R McCarty; Prabin Sharma; Andrew Lange; Julius N Ngu; Ashley Davis; Basile Njei Journal: Bariatr Surg Pract Patient Care Date: 2020-09-14 Impact factor: 0.607
Authors: Kathan Mehta; Palashkumar Jaiswal; Farren Briggs; William A Faubion; James H Tabibian; Fabio Cominelli; Maneesh Dave Journal: Sci Rep Date: 2018-05-01 Impact factor: 4.379